Vittoria to Present VIPER-101 Data at ASH
The biotech company will share Phase 1 results for its Senza5 CART5 therapy at the 68th American Society of Hematology meeting.
Updated on Nov. 17, 2026 in Biotech

Vittoria Biotherapeutics will present Phase 1 VIPER-101 results for Senza5 CART5 in an oral session on December 14, 2026, at the 68th American Society of Hematology Annual Meeting in New Orleans. The company will also present LampTAC degrader platform data in a poster session the same day.
Why it matters
The presentation follows the announcement of FDA RMAT designation for Senza5 CART5, which was supported by this dataset. The VIPER-101 study evaluates the therapy in patients with relapsed or refractory T-cell lymphoma.
The VIPER-101 abstract reports an 88% overall response rate and a 75% complete response rate in relapsed or refractory T-cell lymphoma. The source does not provide sample size, follow-up duration, or a comparator group, so the durability of these responses remains unclear.
The players
Vittoria Biotherapeutics, Inc.
A clinical-stage immunotherapy company headquartered in Philadelphia that is developing Senza5 CART5 and the LampTAC degrader platform.
Stefan K. Barta, M.D., M.S.
A physician affiliated with Penn Medicine who is the author of the VIPER-101 oral presentation.
The details
The oral presentation, authored by Stefan K. Barta, M.D., M.S., of Penn Medicine, highlights clinical activity, CAR-T persistence, immune reconstitution, and delayed immune-mediated adverse events. LampTAC, a modular genetically encoded protein degradation platform, showed cell-intrinsic protein degradation in preclinical findings without genome editing.
Timeline
December 12-15, 2026: 68th ASH Annual Meeting in New Orleans, Louisiana.
December 14, 2026, 3:00-3:15 PM CT: VIPER-101 oral presentation at the Ernest N. Morial Convention Center.
December 14, 2026, 6:00-8:00 PM CT: LampTAC poster presentation at MCCNO Hall F.
Roadmap
The VIPER-101 presentation extends the FDA RMAT designation granted to Senza5 CART5 by publicly releasing the clinical dataset that supported it. The company plans to advance the therapy into a pivotal study, placing it on a path toward a potential later-stage program.
For patients with relapsed or refractory T-cell lymphoma, the data signal a possible future treatment option, though it remains in early clinical development. Patients and clinicians can follow the full ASH presentations for details on safety and durability once they are published.
The takeaway
Early Phase 1 response rates are a first signal rather than proof of benefit, so the full data on durability and safety will be the key measures to watch as the program moves toward a pivotal study.
What happens next
The company plans to advance Senza5 CART5 into a pivotal study, with the ASH presentations scheduled for December 14, 2026.
Further reading
Explore more Biotech coverage for context on clinical-stage cell therapy development.






